KDM6B and neoplasm: Genetic and pharmacologic inhibition of polycomb H3K27me3 demethylases KDM6A and KDM6B sensitized cisplatin-resistant and wild-type TGCT cells to cisplatin and produced dramatic synergistic tumor regression in animal models.